Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 799 results for "genentech"

Genentech Posts Results of ocrelizumab in 2 Phase III Studies ...

Genentech reports positive results from two pivotal studies evaluating the investigational medicine ocrelizumab compared with interferon beta-1a (Rebif), a standard-of-care therapy, in people with relapsing multiple sclerosis (MS), the most common ... Individual.com, 22 hours ago
[x]  

90 images for genentech

TheStreet.com, 1 day ago
Business Insider Australia, 3 days ago
Pharmacy Practice News, 1 week ago
Irish Times, 2 weeks ago
Pharmacy Practice News, 1 week ago
SF Weekly, 1 week ago
SF Weekly, 1 week ago
SF Weekly, 1 week ago
GreenBiz, 1 month ago
MedCity News, 3 weeks ago

Exelixis: FDA Extends PDUFA Action Date For Review Of NDA For Cobimetinib

Biopharmaceutical company Exelixis (EXEL) Wednesday said its partner Genentech informed that, in order to accommodate its review of a supplemental data submission, the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act ...
 RTTNews.com1 day ago FDA taps the brakes on Genentech's cobimetinib review  FierceBiotech1 day ago FDA extends review of Roche, Exelixis' melanoma drug cobimetinib by three months  FirstWord Pharma1 day ago FDA extends PDUFA date for review of cobimetinib NDA; Exelixis off 8%  Seeking Alpha1 day ago

Genentech receives FDA breakthrough therapy designation for scleroderma drug

Genentech Inc., a biotechnology company, has received breakthrough therapy designation status from the FDA for Actemra, indicated for the treatment of systemic sclerosis, also known as scleroderma. "The development of Actemra in systemic sclerosis ...
 Individual.com1 week ago
TheStreet.com

Exelixis (EXEL) Provides Update On Genentech (RHHBY)'s Pending New Drug Application For Cobimetinib, An Exelixis-Discovered Compound 7/1/2015

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Yesterday, Exelixis (NASDAQ:EXEL) partner Genentech, a member of the Roche Group, informed Exelixis that, in order to accommodate its review of a supplemental data submission, the U.S.
 ClinicSpace1 day ago Exelixis : Provides Update on Genentech's Pending New Drug Application for Cobimetinib, an Exelixis-Discovered Compound  4 Traders1 day ago Exelixis Provides Update on Genentech's Pending New Drug Application for Cobimetinib, an Exelixis-Discovered Compound  Yahoo! Finance UK and Ireland1 day ago
[x]  

Expert Panel on "The New Patient Experience" Organized by PRC Clinical at Genentech

 Securities Technology Monitor1 week ago Expert Panel on The New Patient Experience Organized by PRC Clinical at Genentech  BizWire Express1 week ago
[x]  

Genentech's Ocrelizumab Wows in Late Stages and Eyes $18 Billion MS Market

June 30, 2015 By Mark Terry , BioSpace.com Breaking News Staff South San Francisco, Calif.-based Genentech ( RHHBY ) announced today that its clinical studies of ocrelizumab compared to interferon beta-1a (Rebif) in relapsing multiple ...
 BioSpace2 days ago Genentech (RHHBY)'s Ocrelizumab Wows in Late Stages and Eyes $18 Billion MS Market 7/1/2015  ClinicSpace11 hours ago

Studies from Genentech, Inc. Have Provided New Data on Basal Cell Cancer (A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy...

Studies from Genentech, Inc. Have Provided New Data on Basal Cell Cancer (A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma) By a News Reporter-Staff News Editor ...
 4 Traders1 day ago

The Power of Being a Genentech Alumni

The web of Genentech Inc. alumni is vast, intersecting and sought out by investors and biotech companies of all sizes. Grab a "Genenexer" for your board of directors or land one for your executive ranks or your science team, then your company wins ...
 BioSpace1 day ago The Power of Being a Genentech (RHHBY) Alumni 7/1/2015  ClinicSpace1 day ago

Investigational MS Tx Reduces Relapse Rate in Trials

Share this article: Genentech announce positive results from two Phase 3 studies evaluating ocrelizumab compared with Rebif (interferon beta-1a) in patients with relapsing multiple sclerosis (MS) . OPERA I and OPERA II are randomized, ...
 Monthly Prescribing Reference2 days ago AbbVie announces encouraging results from Phase Ib CLL study  Individual.com1 week ago

Genentech launches trial of Actemra in giant cell arteritis

Genentech announced the launch of a new trial, GiACTA, of its interleukin-6 inhibitor as a steroid-sparing agent in patients with giant cell arteritis at the European League Against Rheumatism Annual European Congress of Rheumatology. Clinical ...
 Orthopedics Today2 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - genentech
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less